

S0040-4020(96)00314-6

IODOCYCLIZATION OF 3-ALKYNYL- AND 3-ALLENYL-2-(SUBSTITUTED AMINO)1-IMIDAZOLIN-4-ONES¹

Michihiko Noguchi, ^{a,*} Hiroshi Okada, ^a Masanori Watanabe, ^b Kumi Okuda, ^a and Osamu Nakamura ^a

- ^a Department of Applied Chemistry, Faculty of Engineering, Yamaguchi University, Tokiwadai, Ube 755, Japan
- b Agrochemical Research Department, Ube Research Laboratory, Corporate Research & Development, Ube Industries Ltd., 1978-5, Kogushi, Ube 755, Japan

Abstract: The iodocyclization of 3-alkynyl-2-(substituted amino)-1-imidazolin-4-ones proceeded in regio- and stereo-selective manner to give bicyclic guanidines, imidazo[1,2-a]imidazole and/or imidazo[1,2-a]pyrimidine. The regiochemistry and reactivity of the cyclization were interpretable by the PM3 MO calculations of the iodonium ion intermediates.

Copyright © 1996 Elsevier Science Ltd

In the previous paper, we described the facile preparation of imidazo[1,2-a]imidazoles and/or imidazo[1,2-a]pyrimidines by the iodocyclization of 3-(alk-2-enyl)-2-(substituted amino)-1-imidazolin-4-ones. The regiochemistry of the cyclization depended on the kind of the substituents of alkenyl moieties and was interpretable on the basis of the PM3 molecular orbital (MO) calculations of the iodonium ion intermediates. Although many examples of regio- and stereo-selective alkene-iodocyclization and its development to key synthetic step of naturally occurring products were found in the literatures, alkyne-iodocyclization reaction were relatively rare. Our attention, therefore, was concentrated on the iodocyclization of 3-alkynyl-2-(substituted amino)-1-imidazolin-4-ones. The alkyne-iodocyclization reaction was less reactive and in some cases the addition of iodine to the triple bond was competitive to each other. Similar cyclization of 3-allenyl substrates was also examined. These cyclizations proceeded regio- and stereo-selectively and the regioselectivity would be discussed using the PM3 MO calculation data of the iodonium ions.

Iodocyclization of 3-Alkynyl-2-(substituted amino)-1-imidazolin-4-ones

Preparation of the starting materials, 1-imidazolin-4-ones, was similar to that of the corresponding alkenyl substrates. Ethyl 2-methyl-2-(N'-substituted)carbodiimidopropionates (4), formed *in situ* by the reaction of iminophosphorane 2 with isocyanates 3, were allowed to react with alkynylamines 5-8 to give imidazolinones 9-12 in fair to moderate yields (Scheme 1 and see Experimental section).

The results of iodocyclization of imidazolinones **9** and **10** (R^1 = H) are summarized in Table 1. The reaction of 2-anilino-3-(prop-2-ynyl)-1-imidazolinone (**9a**) with iodine (3.0 equiv.) in dimethoxyethane (DME) at room temperature for 1 day gave 5-exo cyclization product, 2-(iodomethylene)-6,6-dimethyl-1-phenyl-2,3-dihydro-1*H*-imidazo[1,2-a]imidazol-5(6*H*)-one (**13a**), in 77% yield. The structure of **13a** was accomplished on the basis of the analytical and spectroscopic data; its 1H and ^{13}C NMR spectra were quite similar to those of 6,6-dimethyl-2-methylene-1-phenyl-2,3-dihydro-1*H*-imidazo[1,2-a]imidazol-5(6*H*)-one (**14a**)¹ except for the iodomethylene moiety. In its ^{13}C NMR spectrum the olefin carbon attached to iodine atom was shielded by the iodine atom and observed at δ = 47.2 (the exo methylene carbon of **14a** was observed at δ = 84.5). The configuration of the exo-methylene moiety of **13a** was deduced to be *E*-configuration from the nuclear Overhauser effect (NOE) measurements; the irradiation of phenyl protons caused 6.4% enhancement of the olefin proton signal at δ = 5.28. However, no NOEs were observed between the olefin proton (δ = 5.28) and the methylene protons at the 3-position (δ = 4.34). The iodocyclization of 2-(1-naphthylamino) substrate **9c** gave 5-

Scheme 1

Scheme 2

Table 1. Reaction of 3-Alkynyl-5,5-dimethyl-2-(substituted amino)-1-imidazolin-4-ones **9** and **10** with lodine.

Entry	Substrate	R	Base (equiv.)	Time (h)	Products (Yield; %)a	
1	9a	Ph	none	24	13a (77)	
2	9a	Ph	K2CO3 (1.0)	6	13a (81)	
3	9a	Ph	KHCO ₃ (2.0)	3	13a (74)	
4	9c	1-Naphthyl	none	24	13c (87) 15c (3)	
5	9d	Ts	none	24	13d (54) 15d (26)	
6	10a	Ph	none	24	16a (52)	
7	10a	Ph	K2CO3 (1.0)	8	16a (89)	
8	10b	m-Tolyl	none	24	16b (80)	
9	10b	<i>m</i> -Tolyl	K2CO3 (1.0)	24	16b (81)	
10	10d	Ts	none	24	16d (67) 17d (8)	

a Based on the isolated products.

exo cyclization product 13c together with a trace of diiodide 15c. On the other hand, the iodocyclization of 2-tosylamino substrate 9d gave 5-exo cyclization product 13d and diiodide 15d in a ratio of 2:1 (Scheme 2). Similar reaction of 2-anilino- 10a and 2-(m-toluidino)-3-(but-3-ynyl)-1-imidazolinone 10b with iodine gave 6-exo cyclization products 16a and 16b. In the former case, utilizing potassium carbonate as a scavenger of hydrogen iodide resulted in an improvement of the yield. The reaction of 3-(but-3-ynyl)-2-tosylamino-1-imidazolinone 10d with iodine afforded the corresponding 6-exo cyclization product 16d and diiodide 17d in 67 and 8% yields, respectively. The configuration of the exo-methylene moieties in the 6-exo cyclization products 16 was assumed to be (E)-configuration from the chemical shifts of the olefin proton in their ¹H NMR spectra and the possible reaction pathway. The reaction pathway to the 5-exo and 6-exo cyclization products was explained by the formation of three membered cyclic iodonium ion intermediates and the successive ring opening by the intramolecular attack of nitrogen atoms. The regiochemistry of the cyclization and the formation of diiodides 15 and 17 are discussed later using the results of PM3 MO calculations of the corresponding iodonium ion intermediates.

Our concern was focused on the reaction of 3-(but-2-ynyl)- 11 and 3-(3-phenylprop-2-ynyl)imidazolinones 12 with iodine; when a solution of 2-anilino-3-(but-2-ynyl) substrate 11a and iodine in DME was allowed to stir at room temperature for 1 d, 5-exo cyclization product 18a and 6-endo one 19a were formed in 14 and 77% yields, respectively. The structures of the products 18a and 19a were also established by their analytical and spectroscopic data in comparison with those of the related systems such as 13 and 1-substituted imidazolinidazolones 14¹ and 2,2-dimethyl-8-tosyl-7,8-dihydroimidazo[1,2-a]pyrimidin-3(2H)-one (20). Especially, the chemical shifts of the carbonyl carbon were useful for the assignment of the 5-exo cyclization

Scheme 3

Me NHPh R1 12, DME, rt Me Me NHTs
$$R^{1}$$
 1 d Me R^{1} $R^{$

product 18a, imidazoimidazolone (δ = 180.1), and the 6-endo one 19a, imidazopyrimidinone (δ = 183.7). The configuration of the exo-methylene moiety in 18a was tentatively assigned to be (E)-configuration. The similar reaction of 2-anilino substrate 12a with iodine gave the 6-endo product 21a (δ CO= 183.8) in 86% yield. Considerably different results were obtained in the reaction of 2-tosylamino substrates 11d and 12d with iodine; mixtures of unidentified products, probably due to the decomposition of the starting materials, were formed along with the 6-endo cyclization product 22d (δ CO= 183.0) and diiodides 23d and 24d (Scheme 3).

In order to discuss the regiochemistry of the iodocyclization, the PM3 MO calculations of the corresponding iodonium ions 25-28 were examined on the assumption that this iodocyclization would proceed via the iodonium

Table 2. Energy Levels of the Frontier Orbitals of the Iodonium Ions **25-28** and Their Frontier Electron Densities for Nucleophile [fr(N)] in the *exo*- and *endo*-Cyclizations.

						Frontier Electron Density		
				Energy Level (eV)		for Nucleophile [fr(N)]		
Entry	Iodonium ion	R	Rl	HOMO	LUMO	C5-exo	C6-endo	
1	25a	Ph	H	- 11.962	- 6,722	0.442	0.277	
2	25d	Ts	Н	- 12.131	- 6,204	0.453	0.204	
3	27a	Ph	Me	- 11.925	- 6.495	0.341	0.385	
4	27d	Ts	Me	- 12.067	- 6.020	0.307	0.345	
5	28a	Ph	Ph	- 11.189	- 6.895	0.022	0.741	
6	28d	Ts	Ph	- 12.334	- 6.453	0.025	0.740	
						C6-exo	C7-endo	
7	26a	Ph	Н	- 11.121	- 6.577	0.450	0.253	
8	26d	Ts	H	- 11.825	- 6.5 00	0.451	0.239	

ion intermediates. The frontier electron densities for nucleophile [fr(N)] in the 5-exo and 6-endo cyclizations of the LUMOs of the ions 25, 27, and 28, and those in the 6-exo and 7-endo cyclizations of the ion 26 are demonstrated in Table 2. Both iodonium ions 25a,d from 9a and 9d have lager fr(N) at the C-5 position than those at the C-6 position. A similar tendency of the exo-predominance is observed in the iodonium ions 26a,d from 10a and 10d. This suggests that the 5-exo and 6-exo cyclizations are predominant in the ions 25 and 26, respectively. The iodonium ions 27a,d and 28a,d have larger fr(N) values at the C-6 position than those at the C-5 position. This also suggests that the 6-endo cyclizations are predominant in the ions 27 and 28. regiochemistry of these iodocyclizations is consist with the results of the PM3 MO calculation data of the corresponding iodonium ion intermediates. The formation of diiodides 15d, 23d, and 24d could be explained also by the calculation data: the frontier electron densities for electrophile [fr(E)] of the HOMOs of the tosylamino-type iodonium ions 25d, 27d, and 28d are located to the three nitrogen atoms and C-2 atom. On the other hand, the fr(E) of the anilino-type iodonium ions 25a, 27a, and 28a are located to the N-1, anilino nitrogen atom, C-2 atom and anilino phenyl.⁴ This suggests that the both amino nitrogens of the anilino- and tosylamino-moieties in these ions could participate in the iodocyclization. A considerable difference between the HOMO and LUMO levels in the tosylamino-type ion such as 28d seems to be a reason for the exclusive formation of dijodide 24d.

Iodocyclization of 3-Allenyl-2-(substituted amino)-1-imidazolin-4-ones

Although isomerization of propargyl group to allenyl one with a strong base has been well-known, little attention has been paid to the iodocyclizations of allene systems so far.⁵ In the course of this study, we examined the iodocyclization of 3-allenyl-1-imidazolinones. The isomerization of 3-propargyl substrates 9 to 3-allenyl derivatives were examined using potassium *t*-butoxide (*t*-BuOK) according to the reported methods;⁶ only 5,5-dimethyl-3-(propa-1,2-dienyl)-2-tosylamino-1-imidazolin-4-one (29d) could be isolated in a pure form, when the tosylamino substrate 9d was treated with *t*-BuOK in *t*-BuOH at 30 °C. Similarly, 3-(3-phenylpropa-1,2-dienyl)-5,5-dimethyl-2-tosylamino-1-imidazolin-4-one (30d) was formed from imidazolinone 12d (see Experimental section). The reaction of allenyl substrates 29d and 30d with iodine gave the 6-endo cyclization

products 31d and 32d in 46 and 66% yields, respectively (Scheme 4). The structures of the products 31d and 32d were established on the basis of the analytical and spectroscopic data. In the ¹H-¹³C COSY spectra of 31d and 32d as well as their DEPT measurements, the signals assignable to iodomethyl carbon (-CH₂I) and/or iodomethylene one (-CHI-) could not be observed. Their ¹H and ¹³C spectral patterns were similar to those of the 7,8-dihydroimidazo[1,2-a]pyrimidine-3(2H)-ones 33¹ except for the 6-H and 7-C.

Scheme 4

Me NHTs
$$R^1$$
 $\frac{t\text{-BuOK}}{30 \text{ °C}}$ $\frac{t\text{-BuOK}}{2 \cdot 10 \text{ h}}$ $\frac{t\text{-BuOK}}{1 \text{ d}}$ $\frac{t\text{-BuOH}}{1 \text{ d}}$ $\frac{1}{1 \text{ d}}$ $\frac{1}{1$

Conclusion

The iodocyclization of 3-alkynyl-2-(substituted amino)-1-imidazolin-4-ones gave bicyclic guanidines, imidazo[1,2-a]imidazole and imidazo[1,2-a]pyrimidine, in regio- and stereo-selective manners. The regiochemistry of the cyclization was explainable using the fr(N) values of the corresponding iodonium ion intermediates calculated by PM3 MO method. The 3-allenyl-2-tosylamino substrate 30d, obtained from the corresponding 3-alkynyl substrate 12d, showed a higher reactivity than 12d under the iodocyclization conditions. Further application of the iodocyclization to the selective preparation of nitrogen containing heterocycles are in progress in our laboratory.

Experimental

General. For general details of apparatuses and procedures, see the previous paper. ¹ ¹H and ¹³C NMR spectra were measured on a JEOL EX-270 spectrometer (at 270 MHz for ¹H and 68 MHz for ¹³C) in deuteriochloroform solution, unless otherwise stated. Overlapping splitting patterns in ¹H NMR spectra are indicated as ov. Assignment of the NMR spectra of the products was accomplished by ¹H-¹H and ¹H-¹³C COSY spectra. Alkynylamines **5-8** were generated by the reaction of the corresponding hydrochlorides^{8,9} with an excess of triethylamine *in situ*.

Preparation of 1-Imidazolin-4-ones 9-12. General Procedures: To a solution of azide 1 (1.2 mmol) in dry dioxane (5 ml) heated at 80 °C under argon atmosphere was added triphenylphosphine (1.0 mmol) in dry dioxane and immediately nitrogen was extruded. The reaction mixture was stirred for 3 h at the same temperature and cooled down to room temperature. Phenyl isocyanate (3a; 1.0 mmol) was added and stirred for 1 h. Propargylamine hydrochloride⁸ (1.5 mmol) and triethylamine (2.0 mmol) were added to the mixture and stirred at room temperature for 13 h. Evaporation of the solvent, extraction with dichloromethane, and usual column separation [silica gel, hexane-ethyl acetate (4/1)] gave imidazolinone 9a in 36% yield. Similarly, other 1-imidazolin-4-ones 9-12 were obtained and their structures were fully confirmed by the analytical and spectroscopic data. The selected data are summarized as follows:

2-Anilino-5,5-dimethyl-3-(prop-2-ynyl)-1-imidazolin-4-one (**9a**): yield 36%; mp 158-160 °C; 1 H NMR δ =1.34 (6 H, s, 5-Me), 2.23 (1 H, t, J= 2.6 Hz, \equiv CH), 4.42 (2 H, d, J= 2.6 Hz, \Rightarrow NCH₂-), 4.84 (1 H, br s, NH), 6.89, 7.06, 7.32 (total 5 H, Ph). Anal. Found: C, 69.53; H, 6.25; N, 17.18%. Calcd for C₁₄H₁₅N₃O; C, 69.69; H, 6.27; N, 17.42%.

5,5-Dimethyl-2-(1-naphthyl)amino-3-(prop-2-ynyl)-1-imidazolin-4-one (**9c**): yield 37%; mp 161-162 °C; 1 H NMR 8 = 1.33 (6 H, s, 5-Me), 2.31 (1 H, t, 1 = 2.3 Hz, 1 =CH), 4.54 (2 H, d, 1 = 2.3 Hz, 1 =NCH₂-), 4.73 (1 H, br s, NH), 7.03, 7.37-7.49, 7.57, 7.82, 8.11 (total 7 H, aromatic-H). Anal. Found: C, 74.25; H, 5.91; N, 14.40%. Calcd for C₁8H₁7N₃O: C, 74.20; H, 5.88; N, 14.42%.

5,5-Dimethyl-3-(prop-2-ynyl)-2-tosylamino-1-imidazolin-4-one (**9d**): yield 87%; mp 185-186 °C; ${}^{1}H$ NMR δ = 1.45 (6 H, s, 5-Me), 2.15 (1 H, t, J= 2.9 Hz, \equiv CH), 2.42 (3 H, s, Me), 4.29 (2 H, d, J= 2.9 Hz, \Rightarrow NCH₂-), 7.30, 7.86 (total 4 H, Ph), 8.06 (1 H, br s, NH). Anal. Found: 56.63; H, 5.43; N, 12.94%. Calcd for C₁₅H₁₇N₃O₃S: C, 56.42; H, 5.37; N, 13.16%.

2-Anilino-3-(but-3-ynyl)-5,5-dimethyl-1-imidazolin-4-one (**10a**): yield 42%; mp 131-132 °C; 1 H NMR δ= 1.38 (6 H, s, 5-Me), 1.98 (1 H, t, J= 2.6 Hz, \pm CH), 2.64 (2 H, td, J= 6.9, 2.6 Hz, \pm CH₂-C \pm CH), 3.84 (2 H, t, J= 6.9 Hz, >NCH₂-), 4.73 (1 H, br s, NH), 6.96, 7.06, 7.32 (total 5 H, Ph). Anal. Found: C, 70.66; H, 6.78; N, 16.37%. Calcd for C15H₁7N₃O: C, 70.56; H, 6.71; N, 16.46%.

3-(But-3-ynyl)-5,5-dimethyl-1-(m-toluidino)-1-imidazolin-4-one (**10b**): yield 38%; mp 109-111 °C; 1 H NMR δ = 1.38 (6 H, s, 5-Me), 1.97 (1 H, t, J= 2.6 Hz, \equiv CH), 2.33 (3 H, s, Me), 2.68 (2 H, td, J= 6.9, 2.6 Hz, \neg CH₂-C \equiv CH), 3.83 (2 H, t, J= 6.9 Hz, \neg N-CH₂-), 4.75 (1 H, br s, NH), 6.75-7.22 (4 H, ov, aromatic-H). Anal. Found: C, 71.39; H, 7.08; N, 15.48%. Calcd for C₁6H₁9N₃O: C, 71.35; H, 7.11; N, 15.48%.

3-(But-3-ynyl)-5,5-dimethyl-2-tosylamino-1-imidazolin-4-one (**10d**): yield 71%; mp 149-151 °C; ${}^{1}H$ NMR δ = 1,44 (6 H, s, 5-Me), 1.76 (1 H, t, J= 2.6 Hz, Ξ CH), 2.42 (3 H, s, Me), 2.50 (2 H, td, J= 6.9, 2.6 Hz, -CH₂-C Ξ CH), 3.70 (2 H, t, J= 6.9 Hz, >N-CH₂-), 7.29, 7.83, 8.07 (total 4 H, aromatic-H). Anal. Found: C, 57.68; H, 5.73; N, 12.52%. Calcd for C₁₆H₁₉N₃O₃S: C, 57.64; H, 5.74; N, 12.60%.

2-Anilino-3-(but-2-ynyl)-5,5-dimethyl-1-imidazolin-4-one (11a): yield 45%; mp 125-126 °C; ${}^{1}H$ NMR δ = 1.38 (6 H, s, 5-Me), 1.81 (3 H, t, J= 2.3 Hz, \equiv C-Me), 4.37 (2 H, q, J= 2.3 Hz, >N-CH₂-), 4.79 (1 H, br s, NH), 6.98-7.34 (5 H, ov, Ph). Anal. Found: C, 70.75; H, 6.80; N, 16.30%. Calcd for C₁₅H₁₇N₃O: C, 70.56; H, 6.71; N, 16.46%.

3-(But-2-ynyl)-5,5-dimethyl-2-tosylamino-1-imidazolin-4-one (11d): yield 80%; mp 176-177 °C; ${}^{1}H$ NMR δ = 1.45 (6 H, s, 5-Me), 1.71 (3 H, t, J= 2.3 Hz, \equiv CH), 2.43 (3 H, s, Me), 4.23 (2 H, q, J= 2.3 Hz, \Rightarrow N-CH₂), 7.30, 7.87 (total 4 H, aromatic-H), 8.05 (1 H, br s, NH). Anal. Found: C, 57.47; H, 5.73; N, 12.58%. Calcd for C₁6H₁9N₃O₃S: C, 57.64; H, 5.74; N, 12.60%.

2-Anilino-5,5-dimethyl-3-(3-phenylprop-2-ynyl)-1-imidazolin-4-one (**12a**): yield 22%; mp 70-72 °C; 1 H NMR δ = 1.42 (6 H, s, 5-Me), 4.67 (3 H, ov, >N-CH₂- and NH), 6.97-7.48 (10 H, ov, Ph). Anal. Found: C, 75.52; H, 6.38; N, 13.50%. Calcd for C₂₀H₁₉N₃O: C, 75.67; H, 6.03; N, 13.24%.

5,5-Dimethyl-3-(3-phenylprop-2-ynyl)-2-tosylamino-1-imidazolin-4-one (12d): yield 82%; mp 181-182 °C; 1H NMR $\delta=1.47$ (6 H, s, 5-Me), 2.36 (3 H, s, Me), 4.51 (2 H, s, >N-CH₂-), 7.18, 7.25-7.31, 7.86 (total 9 H, aromatic-H), 8.07 (1 H, br s, NH). Anal. Found: C, 63.67; H, 5.32; N, 10.67%. Calcd for C₂₁H₂₁N₃O₃S: C, 63.78; H, 5.35; N, 10.63%.

Iodocyclization of 3-Alkynyl-1-imidazolin-4-ones 9-12. General Procedures: To a solution of imidazolinone **9a** (0.121 g, 0.5 mmol) in DME (5 ml) was added iodine (0.381 g, 1.5 mmol) and the reaction mixture was stirred at room temperature for 1 d under argon atmosphere. The solvent was evaporated, the residue was treated with 5% sodium thiosulfate to decompose the excess of iodine, and extracted with dichloromethane (3 x 15 ml). The organic layer was washed with water, dried over anhydrous magnesium sulfate, and evaporated to dryness. The residue was subjected to column chromatography on silica gel [hexane-ethyl acetate (1/1)] to afford 5-exo cyclization product **13a** (0.141 g, 77%).

2-[(E)-lodomethylene]-6,6-dimethyl-1-phenyl-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5(6H)-one (13a): colorless needles (hexane-benzene); mp 167-168 °C; IR cm⁻¹: 1730 (CO), 1630 (C=N); ¹H NMR δ = 1.41 (6 H, s, 5-Me), 4.34 (2 H, d, J= 2.3 Hz, 3-H), 5.28 (1 H, t, J= 2.3 Hz, =CHI), 7.38-7.54 (5 H, ov, Ph); ¹³C NMR δ = 24.9 (6-Me), 46.1 (=CHI), 47.5 (3-C), 74.5 (6-C), 126.5, 128.5, 130.2, 133.2 (Ph-C), 145.8 (2-C), 156.8

(7a-C), 179.8 (5-C); MS m/z: 367 (M⁺), 352 (M⁺ - Me), 339 (M⁺ - CO). Anal. Found: C, 45.74; H, 3.85; N, 11.44%. Calcd for C₁4H₁4IN₃O: C, 45.79; H, 3.84; N, 11.44%.

 $\begin{array}{l} 2\text{-}[(E)\text{-}Iodomethylene]-6,6-dimethyl-1-(1-naphthyl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5(6H)-one\\ \textbf{(13c)}: colorless crystals; mp 169-170 °C (without recrystallization); IR cm$^{-1}$: 1730 (CO), 1640 (C=N); 1H NMR $$b$= 1.39, 1.42 (each 3 H, each s, 5-Me), 4.54 (1 H, dd, J= 16.1, 2.2 Hz, 3-H), 4.60 (1 H, dd, J= 16.1, 2.6 Hz, 3-H), 4.76 (1 H, dd, J= 2.6, 2.2 Hz, =CHI), 7.52-7.99 (7 H, ov, aromatic-H); 13C NMR $$b$= 24.8, 25.1 (6-Me), 46.4 (3-C), 47.3 (=CHI), 74.6 (6-C), 122.2, 125.9, 126.8, 127.0, 127.4, 128.7, 129.1, 129.3, 134.9 (naphthyl-C), 146.5 (2-C), 157.3 (7a-C), 179.9 (5-C); MS m/z: 417 (M+), 402 (M+ - Me), 290 (M+ - I). Anal. Found: C, 51.90; H, 3.83; N, 9.99%. Calcd for $C_{18}H_{16}IN_{3}O$: C, 51.82; H, 3.87; N, 10.07%.

3-[(E)-2,3-Diiodoprop-2-enyl]-5,5-dimethyl-2-(1-naphthyl)amino-1-imidazolin-4-one (14c) was also obtained in a trace and its structure was supported by the following 1 H NMR spectral data: δ = 1.44 (6 H, s, 5-Me), 4.64 (2 H, d, J= 1.6 Hz, >N-CH₂-), 4.76 (1 H, br s, NH), 7.04-8.21, ov, =CHI and naphthyl-H).

2-[(*E*)-Iodomethylene]-6,6-dimethyl-1-tosyl-2,3-dihydro-1*H*-imidazo[1,2-*a*]imidazol-5(6*H*)-one (13d): colorless needles (ethanol); IR cm⁻¹: 1725 (CO), 1635 (C=N), 1370, 1175 (SO₂); ¹H NMR δ= 1.40 (6 H, s, 6-Me), 2.46 (3 H, s, Me), 4.11 (2 H, d, J= 2.4 Hz, 3-H), 6.88 (1 H, t, J= 2.4 Hz, =CHI), 7.36, 7.93 (total 2 H, aromatic-H); ¹³C NMR δ= 21.7 (Me), 24.4 (6-Me), 47.4 (3-C), 60.2 (=CHI), 75.2 (6-C), 127.9, 130.0, 133.8, 146.5 (aromatic-C), 138.6 (2-C), 154.2 (7a-C), 179.4 (5-C); MS m/z: 445 (M⁺), 417 (M⁺ - CO), 381 (M⁺ - SO₂), 318 (M⁺ - I). Anal. Found: C, 40.52; H, 3.61; N, 9.43%. Calcd for C₁5H₁₆IN₃O₃S: C, 40.46; H, 3.62; N, 9.44%.

3-[(E)-2,3-Diiodoprop-2-enyl]-5,5-dimethyl-1-imidazolin-4-one (**15d**): colorless plates (hexane-benzene); mp 156-157 °C; IR cm⁻¹: 3320 (NH), 1770 (CO), 1620 (C=N), 1380, 1120 (SO₂); ¹H NMR δ = 1.51 (6 H, s, 5-Me), 2.42 (3 H, s, Me), 4.36 (2 H, d, J= 1.5 Hz, >N-CH₂-), 7.10 (1 H, t, J= 1.5 Hz, =CHI), 7.28, 7.84 (total 4 H, aromatic-H), 8.02 (1 H, br s, NH); ¹³C NMR δ = 21.5 (Me), 24.8 (5-Me), 49.4 (>N-CH₂-), 60.6 (5-C), 83.0 (=CHI), 95.7 (-CI=CHI), 126.4, 129.3, 139.1, 143.1 (aromatic-C), 153.6 (2-C), 175.1 (4-C); MS m/z: 573 (M⁺), 446 (M⁺ - I). Anal. Found: C, 31.41; H, 3.00; N, 7.21%. Calcd for C₁5H₁7I₂N₃O₃S: C, 31.43; H, 2.99; N, 7.33%.

7-[(E)-lodomethylene]-2,2-dimethyl-8-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidin-3(2H)-one (16a): colorless prisms (hexane-benzene); mp 165 °C (dec.); IR cm $^{-1}$: 1730 (CO); 1630 (C=N), 1 H NMR δ = 1.29 (6 H, s, 2-Me), 3.04 (2 H, t, J= 6.3 Hz, 6-H), 3.71 (2 H, t, 5-H), 4.86 (1 H, s, =CHI), 7.25-7.52 (5 H, ov, Ph); 13 C NMR δ = 24.6 (2-Me), 29.4 (6-C), 36.3 (5-C), 56.4 (=CHI), 67.0 (2-C), 128.7, 129.0, 130.1, 137.7 (Ph-C), 142.3 (7-C), 149.7 (8a-C), 183.8 (3-C). Anal. Found: C, 47.14; H, 4.21; N, 10.92%. Calcd for C15H16IN3O: C, 47.26; H, 4.23; N, 11.02%.

7-[(E)-Iodomethylene]-2,2-dimethyl-8-(m-tolyl)-5,6,7,8-tetrahydroimidazo[1,2-d]pynimidin-3(2H)-one (16b): colorless needles (hexane-benzene); mp 158-159 °C; IR cm⁻¹: 1720 (CO), 1630 (C=N); ¹H NMR δ = 1.29 (6 H, s, 2-Me), 2.38 (3 H, s, Me), 3.03 (2 H, t, J= 6.3 Hz, 6-H), 3.70 (2 H, t, J= 6.3 Hz, 5-H), 4.83 (1 H, s, =CHI), 7.04-7.40 (4 H, ov, aromatic-H); ¹³C NMR δ = 21.4 (Me), 24.6 (2-Me), 29.4 (6-C), 36.2 (5-C), 56.1 (=CHI), 67.0 (2-C), 126.0, 129.5, 129.7, 129.9, 137.6 (aromatic-C), 142.3 (7-C), 149.7 (8a-C), 183.8 (3-C). Anal. Found: C, 48.90; H, 4.52; N, 10.49%. Calcd for C16H18IN3O: 48.62; H, 4.59; N, 10.63%.

7-[(E)-Iodomethylene]-2,2-dimethyl-8-tosyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidin-3(2H)-one (16d): colorless prisms (ethanol); mp 147 °C (dec.); IR cm⁻¹: 1720 (CO), 1620 (C=N), 1360, 1170 (SO₂); 1 H NMR δ = 1.24 (6 H, s, 2-Me), 2.43 (3 H, s, Me), 2.66 (2 H, t, J= 6.6 Hz, 6-H), 3.44 (2 H, t, J= 6.6 Hz, 5-H), 6.85 (1 H, s, =CHI), 7.30, 7.88 (each 2H, each ov, aromatic-H); 13 C NMR δ = 21.6 (Me), 24.2 (2-Me), 28.2 (6-C), 38.2 (5-C), 67.3 (2-C), 80.7 (=CHI), 128.7, 129.4, 134.8, 145.5 (aromaric-C), 135.4 (7-C), 146.8 (8a-C),

183.4 (3-C). Anal. Found: C, 41.87; H, 4.02; N, 9.04%. Calcd for $C_{16}H_{18}IN_{3}O_{3}S$: C, 41.84; H, 3.95; N, 9.15%.

3-[(*E*)-3,4-Diiodidobut-3-enyl]-5,5-dimethyl-2-tosylamino-1-imidazolin-4-one (**17d**): colorless needles (hexane-benzene); 191-192 °C; IR cm⁻¹: 3380 (NH), 1760 (CO), 1635 (C=N), 1390. 1130 (SO₂); ¹H NMR δ= 1.46 (6 H, s, 5-Me), 2.42 (3 H, s, Me), 2.82 (2 H, t, J= 5.9 Hz, -CH₂-CI=), 3.77 (2 H, t, J= 5.9 Hz, >N-CH₂-), 6.63 (1 H, s, =CHI), 7.28, 7.88 (each 2 H, each ov, aromatic-H), 8.02 (1 H, br s, NH); ¹³C NMR δ= 21.5 (Me), 24.7 (5-Me), 37.1 (-*C*H₂-CI=), 43.6 (>N-CH₂-), 60.1 (5-C), 81.9 (=CHI), 98.2 (-CH₂-*C*I=), 126.6, 129.3, 139.1, 143.2 (aromatic-C), 154.6 (2-C), 175.9 (4-C). Anal. Found: C, 32.91; H, 3.31; N, 7.12%. Calcd for C₁6H₁9IN₃O₃S: C, 32.73; H, 3.26; N, 7.16%.

2-[(E)-1-Iodoethylidene]-6,6-dimethyl-1-phenyl-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5(6H)-one (**18a**): this compound could not be isolated in a pure form. However, its structure was assigned on the basis of its NMR specral data: ¹H NMR δ = 1.38 (6 H, s, 6-Me), 1.96 (3 H, t, J= 2.0 Hz, =CIMe), 4.42 (2 H, q, J= 2.0 Hz, 3-H), 7.33-7.64 (5 H, ov, Ph); ¹³C NMR δ = 24.9 (6-Me), 27.9 (=CIMe), 50.6 (5-C), 70.5 (=CIMe), 74.2 (6-C), 126.8, 128.1, 129.7, 133.2 (Ph-C), 138.0 (2-C), 180.1 (5-C).

6-Iodo-2,2,7-trimethyl-8-phenyl-5,8-dihydroimidazo[1,2-a]pyrimidin-3(2H)-one (**19a**): colorless needles (hexane-benzene); mp 184 °C (dec.); IR cm⁻¹: 1720 (CO), 1620 (C=N); ¹H NMR δ = 1.28 (6 H, s, 2-Me), 1.86 (3 H, t, J= 2.0 Hz, 7-Me), 4.37 (2 H, q, J= 2.0 Hz, 5-H), 7.23-7.48 (5 H, ov, Ph); ¹³C NMR δ = 24.3 (7-Me), 24.6 (2-Me), 49.3 (5-C), 60.5 (6-C), 66.7 (2-C), 128.8, 129.4, 129.6, 135.7 (Ph-C), 138.3 (7-C), 149.1 (8a-C), 183.7 (3-C). Anal. Found: C, 50.36; H, 4.48; N, 10.22%. Calcd for C₁₅H₁₆INO₃• 1/3C₆H₆: C, 52.12; H, 4.42; N, 10.31%.

6-Iodo-2,2,7-trimethyl-8-tosyl-5,8-dihydroimidazo[1,2-*a*]pyrimidin-3(2*H*)-one (22*d*): colorless needles (hexane-benzene); mp 147 °C (dec.); IR cm⁻¹: 1730 (CO), 1650 (C=N), 1360, 1180 (SO₂); ¹H NMR δ= 1.31 (6 H, s, 2-Me), 2.44 (3 H, t, J= 1.7 Hz, 7-Me), 2.46 (3 H, s, Me), 3.89 (2 H, q, J= 1.7 Hz, 5-H), 7.34, 7.86 (each 2 H, each ov, aromatic-H); ¹³C NMR δ= 21.7 (Me), 23.7 (2-Me), 26.1 (7-Me), 48.7 (5-C), 70.2 (2-C), 81.7 (6-C), 128.1, 129.9, 135.2, 145.7 (aromatic-C), 137.1 (7-C), 147.7 (8a-C), 183.0 (3-C). Anal. Found: C, 41.63; H, 4.00; N, 8.88%. Calcd for C₁₆H₁₈IN₃O₃S: C, 41.84; H, 3.95; N, 9.15%.

3-[(*E*)-2,3-Diiodobut-2-enyl)]-5,5-dimethyl-2-tosylamino-1-imidazolin-4-one (**23d**): colorless plates (ethanol); mp 201 °C (dec.); IR cm⁻¹: 3340 (NH), 1760 (CO), 1635 (C=N), 1390, 1135 (SO₂); ¹H NMR δ = 1.50 (6 H, s, 5-Me), 2.42 (3 H, s, Me), 2.51 (3 H, t, J= 1.0 Hz, =CIMe), 4.47 (2 H, q, J= 1.0 Hz, >N-CH₂-), 7.28, 7.83 (each 2 H, each ov, aromatic-H), 8.05 (1 H, br s, NH); ¹³C NMR δ = 21.5 (Me), 24.8 (5-Me), 40.3 (=CIMe), 54.4 (>N-CH₂-), 60.6 (5-C), 95.4, 97.2 (-CI=CIMe), 126.4, 129.3, 139.2, 143.0 (aromatic-C), 153.7 (2-C), 175.3 (4-C); MS m/z: 587 (M⁺), 460 (M⁺ - 1), 380, 334. Anal. Found: C, 32.83; H, 3.26; N, 7.09%. Calcd for C₁₆H₁₉IN₃O₃S: C, 32.73; H, 3.26; N, 7.16%.

Iodocyclization of 3-Allenyl-1-imidazolin-4-ones 29d and 30d. Preparation of 3-Allenyl-1-imidazolin-4-one 29d: A solution of imidazolinone 12d (0.160 g, 0.5 mmol) and t-BuOK (0.067 g, 0.6 mmol) in t-BuOH (6 ml) was heated at 30 °C for 2 h. The solvent was evaporated and the residue was extracted with dichloromethane $(3 \times 15 \text{ ml})$. The dichloromethane was evaporated and the residue was subjected to

column chromatography on silica gel [hexane-ethyl acetate (1/1)] to afford 3-allenyl imidazolinone **29d** (0.078 g, 50%).

The acetylene-allene isomerization of other imidazolinones under similar conditions was carried out to afford the desired products (monitored by TLC). However, usual work-up gave only the starting 3-alkynyl imidazolinones except for **30d**.

10docyclization of 3-Allenyl-1-imidazolin-4-ones 29d and 30d: To a solution of imidazolinone **29d** (0.120 g, 0.37 mmol) in DME (5 ml) was added iodine (0.286 g, 1.1 mmol) and the reaction mixture was stirred at room temperature for 1 d under argon atmosphere. The solvent was evaporated, the residue was treated with 5% sodium thiosulfate to decompose the excess of iodine, and extracted with dichloromethane (3 x 15 ml). The organic layer was washed with water, dried over anhydrous magnesium sulfate, and evaporated to dryness. The residue was subjected to column chromatography on silica gel [hexane-ethyl acetate (1/1)] to afford 6-endocyclization product **31d** (0.059 g, 36%).

5,5-Dimethyl-3-(propa-1,2-dienyl)-2-tosylamido-1-imidazolin-4-one (**29d**): colorless prisms (hexanebenzene); mp 175-176 °C; IR cm⁻¹: 3320 (NH), 1760 (CO), 1620 (C=N, C=C), 1380, 1130 (SO₂); 1 H NMR δ = 1.45 (6 H, s, 5-Me), 2.43 (3 H, s, Me), 5.38 (2 H, d, J= 6.9 Hz, =CH₂), 6.58 (1 H, t, J= 6.9 Hz, >N-CH=), 7.31, 7.86 (each 2 H, each ov, aromatic-H), 8.21 (1 H, br s, NH); 13 C NMR δ = 21.5 (Me), 24.6 (5-Me), 60.5 (5-C), 85.8 (=CH₂), 88.7 (>N-CH=), 126.3, 129.5, 139.0, 143.3 (aromatic-C), 152.5 (2-C), 173.5 (4-C), 204.0 (-CH=C=CH₂); MS m/z: 319 (M⁺), 164 (M⁺ - Ts). Anal. Found: C, 56.41; H, 5.40; N, 13.20%. Calcd for C₁5H₁7N₃O₃S: C, 56.41; H, 5.37; N, 13.16%.

5,5-Dimethyl-3-(3-phenylpropa-1,2-dienyl)-2-tosylamido-1-imidazolin-4-one (**30d**): pale yellow prisms (hexane-benzene); mp 133-135 °C; lR cm⁻¹: 3320 (NH), 1760 (CO), 1620 (C=N, C=C), 1275, 1135 (SO₂); 1 H NMR δ = 1.47 (6 H, s, 5-Me), 2.39 (3 H, s, Me), 6.69 (1 H, d, J= 6.3 Hz, =CH-Ph), 6.90 (1 H, d, J= 6.3 Hz, -CH=), 7.20, 7.24-7.37, 7.76 (total 9 H, aromatic-H), 8.15 (1 H, br s, NH); 13 C NMR δ = 21.5 (Me), 24.7, 24.8 (5-Me), 60.0 (5-C), 91.3 (>N-CH=), 104.1 (=CH-Ph), 126.3, 127.8, 128.0, 128.6, 129.3, 132.7, 138.9, 143.1 (aromatic-C), 152.4 (2-C), 173.4 (4-C), 200.3 (-CH=C=CH-Ph). Anal. Found: C, 63.94; H, 5.18; N, 10.66%. Calcd for C₂₁H₂₁N₃O₃S: C, 63.78; H, 5.35; N, 10.63%.


6-Iodo-2,2-dimethyl-8-tosyl-7,8-dihydroimidazo[1,2-a]pyrimidin-3(2H)-one (31d): colorless needles (hexane-benzene); mp 191-192 °C; IR cm⁻¹: 1730 (CO), 1660 (C=N), 1640 (C=C), 1360, 1170 (SO₂); ^{1}H NMR δ = 1.28 (6 H, s, 2-Me), 2.44 (3 H, s, Me), 4.53 (2 H, d, J= 1.7 Hz, 7-H), 6.96 (1 H, t, J= 1.7 Hz, 5-H), 7.33, 8.00 (each 2 H, each ov, aromatic-H); ^{13}C NMR δ = 21.7 (Me), 24.5 (2-Me), 53.0 (7-C), 67.5 (6-C), 68.0 (2-C), 124.2 (5-C), 128.9, 129.4, 134.2, 145.6 (aromatic-C), 143.1 (8a-C), 177.2 (3-C). Anal. Found: C, 40.95; H, 3.56; N, 9.33%. Calcd for C15H16IN3O3S: C, 40.46; H, 3.62; N, 9.44%.

6-Iodo-2,2-dimethyl-7-phenyl-8-tosyl-7,8-dihydroimidazo[1,2-a]pyrimidin-3(2H)-one (32d): colorless needles (hexane-benzene); mp 192-194 °C; IR cm⁻¹: 1740 (CO), 1640 (C=N), 1620 (C=C), 1350, 1170 (SO₂); lH NMR δ = 1.27, 1.33 (each 3 H, each s, 2-Me), 2.36 (3 H, s, Me), 6.04 (1 H, s, 7-H), 7.07-7.33 (8 H, ov, 5-H and aromatic-H), 7.69 (2 H, d, J= 8.3 Hz, aromatic-H); 13 C NMR δ = 21.5 (Me), 24.2, 24.5 (2-Me), 66.4 (7-C), 67.9 (2-C), 75.0 (6-C), 123.3 (5-C), 127.5, 128.7, 129.0 x 2, 134.8, 136.5, 144.7 (aromatic-C), 143.3 (8a-C), 177.4 (3-C). Anal. Found: C, 48.27; H, 3.85; N, 7.92%. Calcd for C₂₁H₂₀IN₃O₃S: C, 48.37; H, 3.84; N, 8.06%.

Computational Procedures: All iodonium ion intermediates 25-28 were created and roughly optimized by using MM2 force field calculations in MacroModel (version 3.5a). MO calculations were carried out with PM3 method 11 using MOPAC program (version 6.0) 12 on VAX 4000 in Ube Research Laboratory, Corporation Research & Development, Ube Industries Ltd. All iodonium ion intermediates were fully optimized unless otherwise indicated.

References and Notes

- a) Preparation of Heterocycles Using Functionalized Heterocumulenes. Part 5. b) Part 4 in this series: Watanabe, M.; Okada, H.; Teshima, T.; Noguchi, M.; Kakehi, K. Tetrahedron 1996, 52, 2827.
- 2 For recent reviews: Boivin, T. L. B. Tetrahedron 1987, 43, 3309; Cardillo, G.; Orena, M. Ibid. 1990, 46, 3321.
- For recent papers on ionic alkyne-iodocyclizations: Kitagawa, O.; Inoue, T.; Taguchi, T. Tetrahedron Lett. 1992, 33, 2167; Kitagawa, O.; Inoue, T.; Hirano, K.; Taguchi, T. J. Org. Chem. 1993, 58, 3106; Ren, X.-F.; Turos, E.; Lake, C. H.; Churchill, M. R. J. Org. Chem. 1995, 60, 6468. Also, see references cited therein.
- 4 The fr(E) values of iodonium ions 25a and 25d are summarized.



- For recent papers: Chilot, J.-J.; Doutheau, A; Gore, J. Bull. Soc. Chim. Fr. 1984, 307; Walkup, R. D.; Park, G.; J. Am. Chem. Soc. 1990, 112, 1597; Arseniyadis, S.; Gore, J. Tetrahedron Lett. 1983, 24, 3997; Kinsman, R.; Lathbury, D.; Vernon, P.; Gallagher, T. J. Chem. Soc., Chem. Commun. 1987, 243; Friesen, R. W.; Kolaczewska, A. E. J. Org. Chem. 1991, 56, 4888; Friesen, R. W.; Giroux, A.; Cook, K. L. Tetrahedron Lett. 1993, 34, 5983. Also see references cited therein.
- 6 Marshall, J. A.; DuBay, W. J. J. Org. Chem. 1993, 58, 3435.
- 7 Litchman, W. H.; Grant, D. M. J. Am. Chem. Soc. 1968, 90, 1400; Howarth, O. W.; Lynch, R. J. Mol. Phys. 1968, 15, 431; Miyajima, G.; Takahashi, K. J. Phys. Chem. 1971, 75, 331 and 3766.
- 8 Koziara, A.; Osowska-Pacewicka, K.; Zawadzki, S.; Zwierzak, A. Synthesis 1985, 202.
- 9 Moody, C. J.; Rahimtoola, K. F. J. Org. Chem. 1992, 57, 2105.
- Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrikson, T.; Still, W. C. J. Comput. Chem. 1990, 11, 221.
- 11 Stewart, J. J. J. Comput. Chem. 1989, 10, 209.
- 12 "MOPAC program version 6, QCPE No. 455," 1990, Department of Chemistry, Indiana University, Bloomington, IN 47405.

(Received in Japan 22 January 1996; accepted 22 March 1996)